Clinical Trials
26 trialsNCT04491942 2026-04-13
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06603987 2025-11-19
Using CICS-1 and SPM-011 and ï¼»18Fï¼½FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
Stella Pharma Corporation
Phase 1/2 Enrolling by invitation
NCT05107674 2025-09-09
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
Phase 1 Recruiting
NCT05451849 2025-08-27
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
Phase 1/2 Active not recruiting
NCT06299163 2025-07-23
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Numab Therapeutics AG
Phase 1 Terminated
NCT05714553 2025-07-18
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase 1/2 Terminated
NCT05086692 2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05500508 2024-12-24
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
Phase 1/2 Terminated
NCT01291420 2024-12-09
Dendritic Cell Vaccination for Patients with Solid Tumors
University Hospital, Antwerp
Phase 1/2 Completed
NCT05538572 2024-07-01
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Prelude Therapeutics
Phase 1 Completed
NCT06281860 2024-02-28
PITHAC
Centre Hospitalier Universitaire Vaudois
Phase 1 Unknown
NCT05498597 2023-10-19
AMT-151 in Patients With Selected Advanced Solid Tumours
Multitude Therapeutics Inc.
Phase 1 Unknown
NCT05698238 2023-03-15
CAMP1
Mabpro, a.s.
Phase 1 Not yet recruiting
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT03475953 2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2 Unknown
NCT04430842 2023-01-18
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
Phase 1 Completed
NCT01655225 2022-04-08
A Study of LY3023414 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00066404 2020-05-13
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT00372840 2020-03-02
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
Fox Chase Cancer Center
Phase NA Completed
NCT02585362 2019-01-11
Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program
Kantonsspital Winterthur KSW
Phase NA Completed
NCT02580747 2015-10-20
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
Chinese PLA General Hospital
Phase 1 Unknown
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00002465 2013-11-06
High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00002475 2013-07-10
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00030498 2013-01-16
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT00020579 2012-03-15
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Completed